A RANDOMIZED, DOUBLE-BLIND, THREE-PART, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSS-OVER STUDY TO COMPARE THE PHARMACOKINETICS (PK), SAFETY AND IMMUNOGENICITY PROFILE OF MB04 (PROPOSED ETANERCEPT BIOSIMILAR), EU-SOURCED ENBREL® AND US-LICENSED ENBREL® IN HEALTHY MALE VOLUNTEERS.

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2023
This article has no abstract
Epistemonikos ID: 4204caaa170857363b74aa168e887c07fad4b1e4
First added on: Mar 21, 2025